Genetic Polymorphism Analysis

Takanari Kitazono; Masahiro Kamouchi; Yuji Matsumaru; Masato Nakamura; Kazuo Umemura; Hajime Matsuo; Nobuyuki Koyama; Junko Tsutsumi; Kazumi Kimura

Improve Research Reproducibility A Bio-protocol resource

Home
Protocols

Concise Method

Genetic Polymorphism Analysis

TK Takanari Kitazono

MK Masahiro Kamouchi

YM Yuji Matsumaru

MN Masato Nakamura

KU Kazuo Umemura

HM Hajime Matsuo

NK Nobuyuki Koyama

JT Junko Tsutsumi

KK Kazumi Kimura

This method is extracted from research article: J Atheroscler Thromb, May 2022

Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III)

DOI: 10.5551/jat.63473

Request a Protocol

Ask a question

Favorite

Blood samples (2 mL) were collected from subjects who provided informed consent for genetic polymorphism analysis of CYP2C19 once before Week 8 (Visit 5) of the treatment period after randomization. Genetic analysis was performed by an independent laboratory (SRL Mediserch Inc., Tokyo, Japan). The frequency of genetic polymorphisms of CYP2C19 was calculated by treatment group. Patients were classified as extensive metabolizers, intermediate metabolizers, or poor metabolizers.

This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/4.0/

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

Post a Question

0 Q&A

Share your protocol with your peers.

Submit a Preprint Protocol